Related Experiment Video
Updated: Jul 22, 2026
07:27
The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury
Published on: October 21, 2017
Liver injury in alpha 1-antitrypsin deficiency
1Departments of Pediatrics, Biology, and Physiology, Washington University School of Medicine, St. Louis, Missouri, USA. Perlmutter@al.kids.wustl.edu
Clinics in Liver Disease
|March 10, 2001
Summary
Alpha 1-antitrypsin deficiency is a genetic disorder causing liver disease in children and adults. Understanding its molecular basis aids in preventing liver and lung conditions.
Area of Science:
- Genetics
- Hepatology
- Pulmonology
Background:
- Alpha 1-antitrypsin deficiency is the leading genetic cause of pediatric liver disease.
- It is also linked to adult chronic liver disease, hepatocellular carcinoma, and pulmonary emphysema.
- The condition arises from the retention of a mutant alpha 1-antitrypsin molecule in liver cells, causing liver injury, and uninhibited protease activity in the lungs, leading to emphysema.
Purpose of the Study:
- To explore the biochemical and cell biology of the mutant alpha 1-antitrypsin molecule.
- To advance the understanding of susceptibility to liver injury in this condition.
- To develop novel strategies for preventing associated liver and lung diseases.
Main Methods:
- Biochemical analysis of the mutant alpha 1-antitrypsin molecule.
- Cell biology studies focusing on endoplasmic reticulum retention.
- Investigation of protease activity in lung tissue.
Main Results:
- Identification of mechanisms of mutant alpha 1-antitrypsin molecule retention in hepatocytes.
- Elucidation of the role of uninhibited proteolysis in lung parenchyma damage.
- Advances in understanding disease pathogenesis.
Conclusions:
- Recent research has improved comprehension of alpha 1-antitrypsin deficiency.
- New strategies for preventing liver and lung manifestations are emerging.
- Targeting the mutant protein's biochemistry and cell biology is key.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:21Acute Pancreatitis II: Pathophysiology
The pathophysiology of acute pancreatitis centers on injury to pancreatic acinar cells, which initiates a cascade of harmful intracellular events.This injury leads to premature activation of trypsinogen to trypsin in the pancreas. Trypsin then activates other digestive enzymes, such as chymotrypsin, elastase, and phospholipase A2, which begin breaking down pancreatic tissue. The resulting autodigestion causes local inflammation, tissue swelling, hemorrhage, and fat necrosis.Injured acinar cells...
01:21Chronic Pancreatitis II: Pathophysiology
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...